Drug Trial Radar · NCT02200614
Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Jun 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,509
Actual
Start
Sep 12, 2014
Primary completion
Sep 3, 2018
Study completion Jun 14, 2021
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- Collaborators
- Orion Corporation, Orion Pharma
- First posted
- Jul 25, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer.
Conditions
- Prostate Cancer Non-Metastatic
- Castration-Resistant
Interventions
Darolutamide (Nubeqa, BAY1841788)Drug
Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg.
PlaceboDrug
Matching placebo 2 tablets twice daily with food.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Metastasis-Free SurvivalTime frame: From randomization to the time approximately 385 MFS events were observed (approximately 48 months)
Locations
404 sites in 36 countries. Site status is shown where the registry gives one.
Site not named
Homewood, Alabama
Site not named
Anchorage, Alaska
Site not named
Tucson, Arizona
Site not named
Fountain Valley, California
Site not named
La Jolla, California
Site not named
Laguna Hills, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
San Diego, California
Site not named
Whittier, California
Site not named
Denver, Colorado
Site not named
Denver, Colorado
Site not named
Parker, Colorado
Site not named
Boca Raton, Florida
Site not named
Orlando, Florida
Site not named
Port Saint Lucie, Florida
Site not named
Coeur d'Alene, Idaho
Site not named
Chicago, Illinois
Site not named
Evanston, Illinois
Site not named
Springfield, Illinois
Site not named
Greenwood, Indiana
Site not named
Indianapolis, Indiana
Site not named
Jeffersonville, Indiana
Site not named
West Des Moines, Iowa
Site not named
Wichita, Kansas
Site not named
New Orleans, Louisiana
Site not named
Annapolis, Maryland
Site not named
Baltimore, Maryland
Site not named
Salisbury, Maryland
Site not named
Boston, Massachusetts
Site not named
Grand Rapids, Michigan
Site not named
Royal Oak, Michigan
Site not named
Omaha, Nebraska
Site not named
Omaha, Nebraska
Site not named
Lebanon, New Hampshire
Site not named
Voorhees Township, New Jersey
Site not named
Syracuse, New York
Site not named
The Bronx, New York
Site not named
The Bronx, New York
Site not named
Asheboro, North Carolina
Showing 40 of 404 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.